Document Detail

Selected events following insertion of the Progestasert system.
MedLine Citation:
PMID:  7428359     Owner:  NLM     Status:  MEDLINE    
The incidences of selected events were analyzed following insertion of the PROGESTASERT intrauterine progesterone contraceptive system (IPCS) and following its reinsertion after one year of use. Reinsertion did not interrupt the stabilizing or declining trends in incidences of P.I.D., removals for bleeding/pain, removals for other medical reasons, unplanned pregnancies, moderate/severe menstrual cramps and bleeding, and premenstrual/intermenstrual cramps. Comparison of the incidence of P.I.D. in the U.S. population with postinsertion incidence of P.I.D. in IPCS users indicates that the IPCS does not increase the likelihood that a woman will have P.I.D. over the likelihood that she would have it without use of the IPCS. The incidences of expulsions and intermenstrual spotting and bleeding rose temporarily after reinsertion to about half their previous peaks and then diminished markedly within two months, reverting to the levels and favorable patterns of change established during the first year.
Phase 3 clinical trials (carried out during 1972-1976) of the Progestasert IUD system are reported. In addition, reinsertion was made 1 year later, and side effects associated with both the initial and reinsertion are reported and compared. Reinsertion did not interrupt the stabilizing or declining trends in incidences of pelvic inflammatory disease, removals for bleeding/pain, removals for other medical indications, or removals for pregnancies. In addition, reinsertion did not affect trends pertaining to moderate/severe menstrual cramps/bleeding or premenstrual/intermenstrual cramping incidence. Incidence of pelvic inflammatory disease, when this series is compared with data for the U.S., was not increased among users of the Progestasert IUD system. However after reinsertion, the incidences of expulsions and intermenstrual spotting and bleeding did rise temporarily to about half their previous peaks with initial insertion, but they diminished markedly within 2 months of reinsertion and reverted to levels and favorable patterns of change which had been established during the first year of IUD use.
Y Gibor; C Mitchell
Related Documents :
20833619 - Preventing unintended pregnancy: pharmacists' roles in practice and policy via partners...
7032839 - Intrauterine contraception with nova-t and copper-t-200 during three years.
1268519 - Letter: iud and congenital malformation.
24041469 - Characteristics of nigerian women taking sulfadoxine/pyrimethamine twice during pregnan...
2112079 - Comparison of the clinical performance, contraceptive efficacy and acceptability of lev...
7982259 - A cost-benefit analysis of four hormonal contraceptive methods.
6822969 - Circulating oestrogen concentrations during pregnancy in the african elephant (loxodont...
8253919 - The choice of treatment for anovulation associated with polycystic ovary syndrome follo...
7195529 - Management of genital herpes simplex virus infection during pregnancy.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Contraception     Volume:  21     ISSN:  0010-7824     ISO Abbreviation:  Contraception     Publication Date:  1980 May 
Date Detail:
Created Date:  1981-01-26     Completed Date:  1981-01-26     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0234361     Medline TA:  Contraception     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  491-503     Citation Subset:  IM; J    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Intrauterine Devices, Medicated / adverse effects*
Menstruation Disturbances / etiology
Pelvic Inflammatory Disease / etiology*
Progesterone / adverse effects*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Serum phospholipid fractionation after the use of long-acting progestational contraceptives.
Next Document:  Effects of oral contraceptives containing 50 microgram estrogen on blood coagulation in non-Caucasia...